It was January 2012, Isaac dribbled the ball; shot it through the hoop, swish! This was a simple moment the 15-year-old athlete who once participated in cross country, soccer and basketball, thought he’d never experience again. Ten months earlier, Isaac was diagnosed with a brain tumor. He became a patient at St. Jude Children’s Research Hospital® and through extensive treatment and care, his cancer is in remission and he is able to play the sports he loves.
Chili’s® Grill & Bar is helping St. Jude patients like Isaac enjoy their own special, everyday moments through the brand’s ninth annual Create-A-Pepper to Fight Childhood Cancer campaign. Participating Chili’s restaurants nationwide and in Puerto Rico are joining in the fight against childhood cancer and other life-threatening diseases. September is National Childhood Cancer Awareness month and through Sept. 26, Chili’s guests can help the cause by donating at their local restaurants and online.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57540-chili-s-create-a-pepper-for-st-jude
St. Jude Children’s Research Hospital patients who completed kindergarten during their treatment for pediatric cancers celebrated at a graduation ceremony.
For the 10th straight year, St. Jude honored 14 patients from around the United States who completed kindergarten while battling life-threatening illnesses like leukemia and brain tumors. Dozens of families and St. Jude doctors, nurses, and staff cheered for the young students, who completed kindergarten in the St. Jude School Program by Chili’s.
Each year, the school program commemorates students who have completed kindergarten coursework with a special ceremony. The children present a song for the families and St. Jude staff, receive their diplomas and celebrate the milestone with their fellow students.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924755-st-jude-celebrates-kindergarten-graduation/
St. Jude Children’s Research Hospital is launching a new series of public service announcements (PSAs) to help raise awareness and deepen the understanding of the hospital’s lifesaving mission through real St. Jude heroes – its patients and families. St. Jude has not produced national PSAs since 2003 and timed this new multichannel campaign to coincide with the hospital’s 50th anniversary.
The PSAs share St. Jude moments through patients and families like 10-year-old Angiel. Angiel and her mom Damaris were planning a trip to Africa for a family reunion when she was diagnosed with osteosarcoma, a type of bone cancer that produced tumors in both of Angiel’s legs. Today, thanks to St. Jude doctors, Angiel can still look forward to visiting family in a foreign land one day. Angiel’s story is just one of several patients featured in the PSAs.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/stjude/46749/
When Kayla Dehnert tells friends and family in Northern California about life as a St. Jude Children’s Research Hospital patient, she pulls out a string of beads taller than she is.
Kayla, 8, of Novato, Calif., is one of hundreds of St. Jude patients who have participated in the hospital’s Legacy Bead program since its launch in 2009. The program offers patients and their families a tangible way to illustrate their journeys using 55 glass beads as unique as the children who collect them. Patients receive vivid green cylindrical beads for blood transfusions; sapphire round beads for lumbar punctures; tear-drop beads in assorted colors for homesickness; and blue, triangle-shaped beads for clinic visits. Other beads mark triumphs such as the completion of radiation or chemotherapy or challenges ranging from cancer’s return to the death of a friend.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58137-st-jude-legacy-bead-program-treatment-milestones-for-children
Doctors at Qatar’s first specialist women’s and children’s hospital Sidra Medicine have successfully separated conjoined twins, marking a first for the country. The surgery establishes an alternative for patients who previously had limited choices for the successful treatment and care of complex pediatric diseases in the region.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8422651-conjoined-twins-find-new-lease-on-life/
Shire plc (LSE: SHP, NASDAQ: SHPG) has recently launched a new educational resource for people with diabetes and their caregivers as part of its HealTogether national awareness program. HealTogether.com is an online community designed to increase awareness and education of diabetic foot ulcers (DFUs) and help patients better understand that DFUs should be treated immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62794-shire-launches-educational-resource-for-diabetes-and-caregivers
Sermo, Inc. (www.sermo.com), the largest online network in the United States exclusive to physicians, today introduced Sermo Mobile, an application that allows physicians to access the country’s greatest concentration of medical knowledge in real-time. Sermo Mobile builds on Sermo’s current web platform, an online resource where physicians from across 68 specialties and all 50 states collaborate, discuss and consult with each other to provide the highest quality care to their patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51104-sermo-launches-real-time-medicine-mobile-app-for-physicians
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
